Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Izzy who wrote (3176)	12/6/1997 11:23:00 PM
From: biao luo	Read Replies (2) of 6136

Here is the article on In Vivo: The Business and Medicine Report (September, 1997, Vol.15(8)), page 78 Biorbitrage ....... "Agouron, too, has done pretty well on the arbitrage front: Japan Tobacco Inc. paid it some $30 million in development and milestone fees for exclusive Asian marketing rights to the drug and for a 50% share of the drug in Europe [W#942456]. Then in January 1997, Roche bought the European rights from the partners for $40 million [W#972066] and added, in July, rights in selected Asian countries for another $6 million [W#972416]. All this would be business as usual for successful biotechs-except that Agouron didn't invent Viracept. The drug came out of Eli Lilly & Co.'s compound library, going to Agouron as part of the January 1994 wrapping-up of the companies' disbanded 1988 alliance." The publisher is Windhover Information Inc. I just wanted to share some facts with other investors. So long.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next